乳腺癌保乳术后全乳放疗瘤床同步补量研究进展

Simultaneous integrated tumor bed boost during whole breast radiotherapy in breast cancer patients after breast‐conserving surgery:a review of the current evidence

放疗为乳腺癌保乳治疗的重要组成部分,目前大分割已成为全乳照射的首选剂量分割模式。瘤床补量可进一步提高局部控制率,推荐高危患者行瘤床序贯补量。随着适形调强放疗的广泛应用,瘤床同步补量提供了剂量学优势和实践便利。本文就乳腺癌保乳术后瘤床补量指征及瘤床同步补量的研究进展进行综述,特别关注全乳常规分割瘤床同步补量和全乳大分割瘤床同步补量的安全性及疗效,并介绍目前正在进行的全乳大分割瘤床同步补量的Ⅲ期随机临床研究。

Radiotherapy is an important treatment modality in breast-conserving therapy of breast cancer.At present,hypofractionation has become the preferred dose schedule for whole breast irradiation.Tumor bed boost can further improve the local control,and sequential boost is recommended for high-risk patients.The widespread application of intensity-modulated radiation therapy provides dosimetric advantages and practical convenience for simultaneous integrated boost.In this review,the indications of tumor bed boost and recent research progress on simultaneous integrated boost were summarized,specifically focusing on the safety and efficacy of simultaneous integrated boost during conventional fractionated or hypofractionated whole breast radiotherapy.Ongoing phaseⅢrandomized clinical trials of simultaneous integrated boost during hypofractionated whole breast radiotherapy were also illustrated.